×

Investigator-Initiated Trials (IITs), Grants, Sponsorships, and Contributions

Heron Therapeutics is committed to supporting programs and activities that inspire best-in-class patient care, medical and scientific education, and patient advocacy.

In alignment with our goals to develop best-in-class medicines for the management of cancer and pain, Heron is focused on initiatives related to the areas of oncology, supportive care oncology, postoperative pain management, and reducing opioid dependence.

Heron will review funding requests from healthcare- or science-related organizations for the following:

  • Investigator-Initiated Trials
  • Medical Educational Grants (including CME accredited programs)
  • Sponsorships
  • Charitable Contributions

As a general guidance for IITs, please note that Heron considers many factors which may include:

  • Scientific and medical merit
  • Relevant areas of research interest

Within the Acute Care Product Portfolio, Heron is interested in research studies where HTX-011 (bupivacaine and meloxicam) would be used in conjunction with non-opioid multi-modal postoperative pain management strategies with a goal of reducing the use of opioids, especially in OB/GYN, general surgery, orthopedic, colorectal, and plastics.

As general guidance for grant requests, please note that Heron considers many factors which may include:

  • Promotes excellence in patient care
  • Meets CME guidelines related to content, venue, and dissemination as applicable
  • Is conducive to an effective and efficient meeting format
  • Educates the broadest target audience at an appropriate and reasonable cost

Heron is committed to complying with all applicable transparency reporting and disclosure obligations, including those relating to state and federal regulations and as stipulated by the National Physician Payment Transparency Program. At this time, Heron can only accept applications from institutions located within the United States.

Funding Requests:

To complete a form and submit a proposal for an IIT click here.

To complete a form and submit a proposal for a grant click here.

To complete a form and submit a proposal for a sponsorship or contribution click here.

Please submit any proposals at least 60 days in advance of a program or event for which funding is being requested.

Any questions regarding Heron’s IIT program can be sent to InvestigatorIT@herontx.com. Any questions regarding Heron’s grant program can be sent to grants@herontx.com.

Sustol

About SUSTOL

SUSTOL® (granisetron) extended-release injection is a serotonin-3 (5-HT3) receptor antagonist that is approved by the U.S. Food and Drug Administration (FDA) and is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Visit sustol.com

Cinvanti

About CINVANTI

CINVANTI® (aprepitant) injectable emulsion, for intravenous use is a substance P/neurokinin-1 (NK1) receptor antagonist that is approved by the FDA and is indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen; and nausea and vomiting associated with the initial and repeat courses of MEC as a 3-day regimen.

In February 2019, the FDA approved the administration of CINVANTI as a 2-minute IV injection (push), providing an alternative to 30-minute IV infusion. CINVANTI is now the only IV NK1 RA that offers the operational flexibility of a 2-minute IV push.

In July 2020, we initiated a Phase 2 clinical study evaluating CINVANTI in early hospitalized patients with Coronavirus Disease 2019 (COVID-19).

Limitations of Use: CINVANTI has not been studied for treatment of established nausea and vomiting.

Visit CINVANTI.com

About HTX-011 (ZYNRELEF™)*

HTX-011 (bupivacaine and meloxicam) is an investigational drug that has not been approved by the FDA. HTX-011 is in development to reduce postoperative pain for 72 hours and reduce the need for opioid analgesics. It is an extended-release, dual-acting local anesthetic™ (DALA™) applied into the surgical site. It utilizes a mechanism of action that combines bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam.

Heron submitted a New Drug Application (NDA) to the FDA for HTX-011 in October of 2018. A complete response letter (CRL) was received from the FDA regarding the NDA for HTX-011 in June 2020, relating to non‑clinical information. No clinical safety or efficacy issues and no chemistry, manufacturing and controls (CMC) issues were identified. Heron resubmitted an NDA to the FDA for HTX-011 in November 2020 and the FDA set a Prescription Drug User Fee Act goal date of May 12, 2021. In April 2021, Heron responded to a list of questions received from Health Canada and we anticipate up to a 300-day review period following screening of the response. In September 2020, the European Commission (EC) granted a marketing authorization for ZYNRELEF (also known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. As of January 1, 2021, ZYNRELEF is approved in 31 European countries including the countries of the European Union and European Economic Area and the United Kingdom.

*ZYNRELEF is the approved trade name for HTX-011 in the European Union and the UK.

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.

Dev Tool:

Request: medical-professionals/grants-and-sponsorships
Matched Rewrite Rule: (.?.+?)(?:/([0-9]+))?/?$
Matched Rewrite Query: pagename=medical-professionals%2Fgrants-and-sponsorships&page=
Loaded Template: page.php